Swissmedic approves Ronapreve for severe COVID-19 treatment
Swissmedic has authorised the monoclonal antibody cocktail Ronapreve, developed by Roche and Regeneron, for use in treating severe COVID-19 in patients at high risk of progression.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthSwissmedic approves Ronapreve for severe COVID-19 treatment
Sign in or subscribeBrowse free archive reportsSwissmedic has authorised the monoclonal antibody cocktail Ronapreve, developed by Roche and Regeneron, for use in treating severe COVID-19 in patients at high risk of progression.